Russell Investments Group, Ltd. Cel Sci Corp Transaction History

Russell Investments Group, Ltd.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 29, 2022	BUY	$2.58 - $4.99 $20,087 - $38,852	7,786 New	7,786 $35,000
Q3 2021 Nov 08, 2021	SELL	$7.64 - $12.49 $254,213 - $415,592	-33,274 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$12.0 - $27.64 $321,852 - $741,332	26,821 Added 415.64%	33,274 $506,000
Q4 2020 Feb 08, 2021	SELL	$11.05 - $16.62 $77,283 - $116,240	-6,994 Reduced 52.01%	6,453 $75,000
Q3 2020 Nov 09, 2020	BUY	$11.69 - $14.54 $157,195 - $195,519	13,447 New	13,447 $171,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Russell Investments Group, Ltd. with notifications on news.